Literature DB >> 8502482

The cdk2 kinase is required for the G1-to-S transition in mammalian cells.

L H Tsai1, E Lees, B Faha, E Harlow, K Riabowol.   

Abstract

In the cell cycle of fission and budding yeast, the p34cdc2/CDC28 kinase is required for both the G1-to-S and G2-to-M phase transitions. In vertebrates, the homologous p34cdc2 kinase is required for G2-to-M phase transitions but appears to be dispensable for DNA synthesis. We have investigated the function of a related kinase, p33cdk2, using serum-stimulated quiescent human fibroblasts. While the p33cdk2 protein was expressed at constant levels throughout the cell cycle, p33cdk2 kinase activity was first detected a few hours prior to the onset of DNA synthesis. Microinjection of anti-p33cdk2 antibodies blocked cells from entering S phase. Pre-adsorption of these antibodies with cdk2 protein abrogated their blocking effect suggesting that the G1 arrest caused by these antibodies is cdk2-specific. These results indicate that p33cdk2 is required for the G1-to-S phase transition in mammalian cells. We also show evidence to suggest that the cyclin E/p33cdk2 complex is likely to be required for entry into S phase since the timing of the cyclin E-associated kinase activity was coincident with that of p33cdk2 and preclearing of either component abolished the majority of the histone H1 kinase activity present in the lysates harvested from the late G1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8502482

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  100 in total

1.  CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.

Authors:  E Vigo; H Müller; E Prosperini; G Hateboer; P Cartwright; M C Moroni; K Helin
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 2.  The G1 restriction point as critical regulator of neocortical neuronogenesis.

Authors:  V S Caviness; T Takahashi; R S Nowakowski
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

Review 3.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription.

Authors:  J Zhao; B K Kennedy; B D Lawrence; D A Barbie; A G Matera; J A Fletcher; E Harlow
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

5.  Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1.

Authors:  P R Andreassen; O D Lohez; F B Lacroix; R L Margolis
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

6.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.

Authors:  Y N Chen; S K Sharma; T M Ramsey; L Jiang; M S Martin; K Baker; P D Adams; K W Bair; W G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

7.  Interaction mating reveals binary and ternary connections between Drosophila cell cycle regulators.

Authors:  R L Finley; R Brent
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells.

Authors:  S J Shiff; L Qiao; L L Tsai; B Rigas
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Exit from G0 and entry into the cell cycle of cells expressing p21Sdi1 antisense RNA.

Authors:  M Nakanishi; G R Adami; R S Robetorye; A Noda; S F Venable; D Dimitrov; O M Pereira-Smith; J R Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

10.  A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells.

Authors:  J M Slingerland; L Hengst; C H Pan; D Alexander; M R Stampfer; S I Reed
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.